Skip to content
Review Open access

GClnc1 as an emerging oncogenic regulator with mechanistic insights and clinical implications in human cancers

Oct 2026 · iScience · Vol 29 · 0 citations · 41 references
Medicine

Abstract

Summary Gastric cancer-related long non-coding RNA1 (GClnc1) is an emerging oncogenic regulator in multiple malignancies, including gastric, colorectal, ovarian, and bladder cancers, as well as osteosarcoma. It promotes proliferation, inhibits apoptosis, and enhances drug resistance and metastasis. Mechanistically, GClnc1 dysregulates key cancer-related regulators and pathways, such as p53, MYC, NF-κB, and the SIRT3/SOD2 axis. Clinically, GClnc1 shows diagnostic and prognostic potential across cancers, with aberrant expression in tissues and altered circulating levels. Notably, exosomal GClnc1 serves as a circulating biomarker for early gastric cancer detection and predicts response to fluorouracil-based chemotherapy. This review summarizes current evidence on GClnc1’s regulatory mechanisms and discusses its translational applications. GClnc1 may serve as a multi-cancer biomarker and a promising therapeutic target.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.